Using advanced techniques to find new treatments for relapsed leukemia
Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention
NA · Azienda Ospedaliero-Universitaria di Parma · NCT06626893
This study is testing new treatment options for adults with relapsed leukemia to see if certain molecules can help them respond better to therapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Azienda Ospedaliero-Universitaria di Parma (other) |
| Locations | 8 sites (Meldola, Forlì-Cesena and 7 other locations) |
| Trial ID | NCT06626893 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to explore new therapeutic targets for patients with relapsed or refractory Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) using integrative 'omics' approaches. By employing next-generation sequencing and functional analyses, the study seeks to identify molecules with known biological activity that could serve as potential new treatments. The trial will include at least 100 patients aged 18 and older who have experienced disease recurrence after prior therapies. The primary focus is to determine if these identified molecules can lead to effective therapeutic strategies based on patient-specific response profiles.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 with relapsed or refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia after at least one line of therapy.
Not a fit: Patients who have not been diagnosed with relapsed or refractory leukemia or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new, targeted treatment options for patients with difficult-to-treat forms of leukemia.
How similar studies have performed: Other studies utilizing 'omics' approaches have shown promise in identifying new therapeutic targets, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients to be enrolled in the study must have a diagnosis of AML, B ALL/LBL, T ALL/LBL, MPAL/AUL as described by WHO 2016 classification and must complained relapsed or refractory disease after at least one line of therapy * Ages Eligible for Study: over 18years * Patients must have greater than 5% blasts in the bone marrow with or without extramedullary disease * Patients with must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis * Patients may be enrolled on study regardless of the timing of prior I therapy * Patients must be capable of understanding the investigational nature and the objectives of the study. All patients must sign a written informed consent. Exclusion Criteria: \-
Where this trial is running
Meldola, Forlì-Cesena and 7 other locations
- IRST-IRCCS Meldola — Meldola, Forlì-Cesena, Italy (RECRUITING)
- A.O.U. Bologna — Bologna, Italy (RECRUITING)
- A.O.U. Ferrara — Ferrara, Italy (RECRUITING)
- AOU Parma — Parma, Italy (RECRUITING)
- Piacenza Hospital - AUSL Piacenza — Piacenza, Italy (RECRUITING)
- Ravenna Hospital - AUSL Romagna — Ravenna, Italy (RECRUITING)
- A.O. Reggio Emilia — Reggio Emilia, Italy (RECRUITING)
- Rimini Hospital-AUSL Romagna — Rimini, Italy (RECRUITING)
Study contacts
- Study coordinator: Benedetta Cambò, MD
- Email: bcambo@ao.pr.it
- Phone: 0521 704446
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic